Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Cytokinetics Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.67 (market cap $384.59M), while Cytokinetics Inc trades at $62.02 (market cap $8.50B). The key difference: Cytokinetics Inc is far larger — about 22.1× YieldMax COIN Option Income Strategy ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and Cytokinetics Inc for 19 Days on average.
| CONY | CYTK | |
|---|---|---|
Market Cap | $384.59M | $8.50B |
Volume | 792,653 | 2,395,556 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $87.26 |
52-Week Low | $17.73 | $54.76 |
Typical Hold Time | 41 Days | 19 Days |
Enterprise Value | — | $8.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.16, down 3.38% today, with a bearish technical outlook as moving averages signal selling pressure. The ETF maintains weekly dividend distributions but faces structural NAV erosion concerns. Recent news highlights regulatory uncertainty impacting crypto-related stocks after Senate cryptocurrency legislation failed to advance.
The outlook remains challenging with significant YTD price decline and ongoing NAV decay despite high distribution rates. Investment opportunity exists for income-focused investors seeking weekly dividends, but structural risks and crypto market volatility present substantial downside exposure.
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
